Cyclooxygenase products and atherosclerosis
- 31 May 2008
- journal article
- review article
- Published by Elsevier in Drug Discovery Today: Therapeutic Strategies
- Vol. 5 (1), 25-36
- https://doi.org/10.1016/j.ddstr.2008.05.006
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Protection of atherogenesis in thromboxane A2 receptor-deficient mice is not associated with thromboxane A2 receptor in bone marrow-derived cellsBiochemical and Biophysical Research Communications, 2006
- Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesisProceedings of the National Academy of Sciences, 2006
- Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular functionJCI Insight, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJCI Insight, 2005
- Prostacyclin protects against elevated blood pressure and cardiac fibrosisCell Metabolism, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With HypertensionHypertension, 2003
- Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivoJCI Insight, 1999
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Prostaglandin endoperoxide synthase: structure and catalysisBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991